BrightPath Biotherapeutics Co., Ltd.
4594 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 川崎市川崎区殿町三丁目２５番２２号
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BrightPath Biotherapeutics Co., Ltd. is a pioneering Japanese biotechnology company specializing in innovative cancer therapies. The company focuses on developing iPS-NKT, a groundbreaking allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to generate natural killer T-cells (NKT cells) for cancer treatment. Recognizing the therapeutic potential of NKT cells, which exhibit diverse anti-tumor effects yet are typically scarce in the bloodstream, BrightPath harnesses state-of-the-art iPSC technology to produce these cells in large, homogeneous quantities from its iPS Master Cell Bank. By leveraging this novel approach, BrightPath aims to advance cancer treatment and improve patient outcomes through effective and scalable cell therapies.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-20 09:01 |
Inside Information Statement
臨時報告書
|
Japanese | 22.8 KB | |
| 2025-06-19 08:36 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2025-06-19 08:32 |
Internal Control over Financial Reporting
内部統制報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 23.4 KB | |
| 2025-06-19 08:25 |
Annual Report
有価証券報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 933.5 KB | |
| 2024-11-08 07:35 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-11-08 07:34 |
Interim Report
半期報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 224.9 KB | |
| 2024-06-21 09:07 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 254.0 KB | |
| 2024-06-21 08:34 |
Internal Control over Financial Reporting
内部統制報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 23.2 KB | |
| 2024-06-21 08:33 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-06-21 08:32 |
Annual Report
有価証券報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 990.5 KB | |
| 2024-06-19 08:00 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 513.9 KB | |
| 2024-02-09 07:12 |
Regulatory News Service
確認書
|
Japanese | 9.1 KB | |
| 2024-02-09 07:11 |
Quarterly Report
四半期報告書－第21期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 195.3 KB | |
| 2023-11-15 07:27 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 183.0 KB | |
| 2023-11-14 07:56 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 332.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |